logo
Wall Street's 'Doctor Doom' tells BI about his move into money management, where he's off to a market-beating start

Wall Street's 'Doctor Doom' tells BI about his move into money management, where he's off to a market-beating start

Yahoo30-05-2025
Nouriel Roubini's America Atlas Fund has outperformed amid market volatility and inflation risks.
Roubini's fund launched in November 2024 and is up 4%.
The fund has heavy allocations to short-term Treasurys and gold.
On a cold night in December, Nouriel Roubini stood in a dark room at Bloomberg's Manhattan headquarters and prophesied a menacing future for financial markets.
Yields on 10-year Treasurys would soar to 8% thanks to persistent inflation, he said at Bloomberg's ETFs in Depth conference. That would send the S&P 500 and Nasdaq plummeting.
The scene was perfectly on brand for the famously bearish economist widely known as Dr. Doom. That's why it might have been easy to dismiss his gloomy proclamations. Perhaps even more of a reason to discount Roubini's warnings was that he had just launched an ETF, the America Atlas Fund (USAF), meant to act as an alternative to the fixed-income segment of the traditional 60/40 portfolio. A cynical listener could have interpreted his speech as a pitch to buy his product because stocks and bonds would perform poorly.
But six months later, the evidence is irrefutable: Roubini has nailed his opening act as a fund manager.
Since USAF's launch in November, the S&P 500 is flat, suffering a violent 20% drawdown in the interim. Long-end Treasurys have also been volatile, and have sold off in tandem with stocks. Many of the driving forces behind those moves have been those inflation risks that Roubini warned of, including tariffs and restoring, and government spending.
Meanwhile, USAF is up 4% and fell only 2% during the market's "Liberation Day" tantrum when stocks tanked and bond yields spiked. The fund has been volatility-resistant thanks to its heavy allocations to short-end Treasurys (about 50% of the portfolio) and gold (19%). The remaining holdings are a mix of commodities, REITs, and TIPS, and alternative investments.
In other words, Roubini's timing couldn't have been better, and his warnings — at least directionally speaking — have been spot on.
It's been a dream start for the New York University professor, who often gets flak for his regular pessimism.
"Sometimes people say, 'You talk about stuff, but talk is cheap,'" Roubini told BI. "'Put your money where your mouth is. Have some skin in the game.'"
The 67-year-old Roubini, who is most known for predicting the 2008 financial crisis, could have simply kept on with his work at NYU and continued pontificating about where the economy was headed.
But the economist wanted to take on a fresh challenge.
"In different stages in life, you do different things," he said.
In the final chapter of Roubini's 2022 book, "MegaThreats: Ten Dangerous Trends That Imperil Our Future, And How to Survive Them," he lays out how investors might protect themselves from downside risks. In recent years, he decided it was time to put those ideas to the test.
It has always been a logical next step for him to wade into the world of asset management, he said. Plus, it's a chance to respond to his many detractors who have questioned the weight behind his predictions since he didn't have any money under his purview.
"After a career in academia, of policy, of providing economic advice, more and more people say, 'If you are that smart, why don't you try to also manage money rather than just talking about it," he continued. "So it was a natural thing that would have eventually happened."
It remains to be seen if Roubini can keep his string of success going in the years ahead. The outlook informing his positioning is that persistent inflation in the 5-6% range will continue to put upward pressure on 10-year Treasury yields. That's why he's sitting heavily in short-term Treasurys at the moment, collecting a similar yield to longer-term assets while not having to endure the same volatility. If 10-year rates were to get up toward 8%, that would be the right time to buy in, he said.
His views on inflation are well above the consensus in markets and among Wall Street banks, though it's still unclear what impact tariffs and potential tax cuts will have on consumer prices. If inflation fears dissipate, Roubini's exceptionally well-timed introduction to the asset management space may very well prove to be beginner's luck.
Either way, investors now have a way to grade Roubini's forecasts in real time.
"One thing is to talk about money, and another is managing it," Roubini said. "You see right away the feedback between your ideas and what happens in the real markets."
Read the original article on Business Insider
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Amgen Stock Sinks As Market Eyes MariTide's Next Move
Amgen Stock Sinks As Market Eyes MariTide's Next Move

Yahoo

time15 minutes ago

  • Yahoo

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday. The US drug maker reported adjusted earnings of $6.02 per share, up 21% year over year, beating the consensus of $5.24. Amgen reported quarterly sales of $9.18 billion, up 9%, beating the Wall Street estimate of $8.87 sales grew 9%, driven by 13% volume growth, partially offset by 3% lower net selling price. Fifteen products delivered at least double-digit sales growth in the second quarter. Outlook Following the strong quarterly performance, Amgen raised fiscal year 2025 adjusted earnings guidance from $20.00-$21.20 per share to $20.20-$21.30 versus the consensus of $20.89. The company raised sales outlook from $34.30 billion-$35.70 billion to $35 billion-$36 billion versus the consensus of $35.29 billion. MariTide in Focus Despite the positive financial results, investor focus remains squarely on the company's experimental weight-loss drug, MariTide. A William Blair analyst noted that investors are 'hyper-focused' on the drug's progress. Part 2 of the Phase 2 chronic weight management study is ongoing in obese patients, with or without type 2 diabetes. Data readout is anticipated in the fourth quarter of 2025. View more earnings on AMGN A Phase 2 study investigating MariTide for type 2 diabetes is ongoing in adults with and without obesity. Data readout is anticipated in the fourth quarter of 2025. Analyst Matt Phipps of William Blair said, 'Given the trial is solely focused on the maintenance setting, we do not believe it will address the key question of tolerability that investors continue to debate.' Analyst Phipps says Amgen shares are up 15% year-to-date, although it remains volatile as investors debate clinical updates with MariTide given the significant market opportunity and competitive landscape. 'We believe Amgen has had meaningful clinical and commercial success with assets including Repatha, Evenity, Blincyto, Tezspire, Imdelltra, and Uplizna that support continued upside on top of the potentially differentiated profile of MariTide, and therefore reiterate our Outperform rating.' Amgen has some near-term headwinds from legacy products, including the recent launch of a biosimilar to Prolia and Xgeva at the end of May 2025 (recent settlement with Sandoz), and the difficulties in gaining more market share with the biosimilar franchises, but the analyst believes clinical catalysts over the next 6 to 12 months will provide meaningful reasons for investor excitement about the long-term growth prospects of the company. Check out . Price Action: AMGN stock is trading lower by 5.10% to $284.97 at last check Wednesday. Read Next:Photo by JHVEPhoto via Shutterstock Latest Ratings for AMGN Date Firm Action From To Feb 2022 Morgan Stanley Maintains Equal-Weight Feb 2022 Wells Fargo Maintains Equal-Weight Feb 2022 Barclays Maintains Equal-Weight View More Analyst Ratings for AMGN View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? AMGEN (AMGN): Free Stock Analysis Report This article Amgen Stock Sinks As Market Eyes MariTide's Next Move originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio

Northern Trust Leaders to Participate in Barclays Global Financial Services Conference on September 9 th
Northern Trust Leaders to Participate in Barclays Global Financial Services Conference on September 9 th

Business Wire

time16 minutes ago

  • Business Wire

Northern Trust Leaders to Participate in Barclays Global Financial Services Conference on September 9 th

CHICAGO--(BUSINESS WIRE)--Northern Trust Corporation announced today that Chief Financial Officer David Fox and Chief Operating Officer Peter Cherecwich will participate in the Barclays Global Financial Services Conference in New York City on Tuesday, September 9, 2025, at 4:15 p.m. (ET). A live webcast of the event may be accessed via Northern Trust's website ( in the investor relations section. A replay will be available for approximately four weeks after the session date. About Northern Trust Northern Trust Corporation (Nasdaq: NTRS) is a leading provider of wealth management, asset servicing, asset management and banking to corporations, institutions, affluent families and individuals. Founded in Chicago in 1889, Northern Trust has a global presence with offices in 24 U.S. states and Washington, D.C., and across 22 locations in Canada, Europe, the Middle East and the Asia-Pacific region. As of June 30, 2025, Northern Trust had assets under custody/administration of US$18.1 trillion, and assets under management of US$1.7 trillion. For more than 135 years, Northern Trust has earned distinction as an industry leader for exceptional service, financial expertise, integrity and innovation. Visit us on Follow us on Instagram @northerntrustcompany or Northern Trust on LinkedIn. Northern Trust Corporation, Head Office: 50 South La Salle Street, Chicago, Illinois 60603 U.S.A., incorporated with limited liability in the U.S. Global legal and regulatory information can be found at

These 2 stocks are still on our shopping list, and what Eli Lilly needs to deliver on earnings
These 2 stocks are still on our shopping list, and what Eli Lilly needs to deliver on earnings

CNBC

time17 minutes ago

  • CNBC

These 2 stocks are still on our shopping list, and what Eli Lilly needs to deliver on earnings

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: Stocks are nicely higher on Wednesday with the S & P 500 rebounding from a slight dip in the prior session. Apple is one of the big gainers in the session after the White House confirmed to CNBC that the company plans to add another $100 billion to its previous $500 billion manufacturing investment pledge to the United States over the next four years. Apple was also reportedly spared from the recent tariff escalation on goods from India. That one-two punch of good news has sent Apple shares up nearly 6% and on pace for their third session over the past year. Still waiting : It's been about one week, but we are still looking to buy some Starbucks and Palo Alto Networks shares at these levels when our trading restrictions allow. The way our restrictions work is that we're unable to trade any stock that Jim Cramer mentions on CNBC for the next 72 hours. Both stocks got dinged last week: Starbucks sold off on earnings despite CEO Brian Niccol explaining that the coffee chain's turnaround plan was ahead of schedule. And Palo Alto Networks was slammed after it said it was buying CyberArk for $25 billion. This is the largest acquisition in the company's history, which naturally brings some execution risk. However, CEO Nikesh Arora is known for his deal-making. When he says the identity security market is inflecting , making now the best time to enter the category, we want to be there with him. With a more than 1% gain Wednesday afternoon, Palo Alto shares are on track to snap a six-session losing streak that began July 29, the day that The Wall Street Journal first reported on acquisition talks with CyberArk. Up next : Companies reporting after the closing bell on Wednesday include retail darling AppLovin , language learning app Duolingo , cybersecurity provider Fortinet , Airbnb , coffee chain Dutch Bros , and sportsbook DraftKings . Meanwhile, Club name Eli Lilly is set to report earnings before the opening bell on Thursday, and we're looking for combined revenue from Mounjaro and Zepbound to come in above the FactSet consensus estimate $7.73 billion. A raise would be a plus, but Eli Lilly will have to at least maintain its full-year guidance to ease concerns about a potential slowdown in the GLP-1 market, which Novo Nordisk highlighted last week. We trimmed our Lilly position off that Novo news as a hedge against slowing trends. Other companies scheduled to report are electricity provider Vistra , HBO parent Warner Bros. Discovery , Band-Aid owner Kenvue , and aircraft parts maker Parker-Hannifin . On the data side, we'll be on the lookout for weekly jobless claims. This report suddenly has a lot more importance to it following last week's awful jobs number. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store